Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyFORT-1: Phase II/III Study of Rogaratinib vs. Chemotherapy in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression

The researchers believe these are the first data to compare FGFR-directed therapy with chemotherapy in patients with FGFR-altered UC, demonstrating comparable efficacy and manageable safety. Experimentation revealed that FGFR3 DNA alterations in conjunction with FGFR1/3 mRNA overexpression may be better predictors of rogaratinib response.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form